Abstract
Caveolin-1 displays both tumour-suppressor and tumour-promoter properties in breast cancer. Using characterised preclinical cell models for the transition of oestrogen-sensitive (WT-MCF-7 cells) to a tamoxifen-resistant (TAM-R cells) phenotype we examined the role caveolin-1 in the development of hormone-resistant breast cancer. The WT-MCF-7 cells showed abundant expression of caveolin-1 which potentiated oestrogen-receptor (ERα) signalling and promoted cell growth despite caveolin-1 mediating inhibition of ERK signalling. In TAM-R cells caveolin-1 expression was negligible, repressed by EGF-R/ERK signalling. Pharmacological inhibition of EGFR/ERK in TAM-R cells restored caveolin-1 and also resulted in the emergence of pools of phosphorylated caveolin-1. WT-MCF-7 cells exposed to tamoxifen for upto 12 weeks displayed increased caveolin-1 (peaking by week 2) followed (after week 8) by a marked decrease as the cells progress to develop a stable tamoxifen-resistant phenotype. The targeted down-regulation (siRNA) of caveolin-1 in WT-MCF-7 cells reduced growth but did not affect their sensitivity to tamoxifen, suggesting loss of caveolin-1 alone is not sufficient to confer tamoxifen-resistance. Hyperactivation of EGFR/ERK is a feature of tamoxifen-resistant breast cancer cells, a principal driver of cell growth. Recombinant expression of caveolin-1 in TAM-R cells did not affect EGFR/ERK activity, potentially due to mislocalisation of caveolin-1 through hyperactivation of the mTOR pathway or altered caveolin-1 phosphorylation. This work defines a novel role for caveolin-1 with implications for the clinical course of breast cancer and identifies caveolin-1 as a potential drug target for the treatment of early oestrogen-dependent breast cancers. Further, the loss of caveolin-1 may have benefit as a molecular signature for tamoxifen resistance.
Similar content being viewed by others
References
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trails. Lancet 365:1687–1717. doi:10.1016/S0140-6736(05)66544-0
Powles T, Ashley S, Tidy A et al (2000) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283–290. doi:10.1093/jnci/djk050
Clarke R, Leonessa F, Welch J et al (2001) Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53:25–71
Nicholson R, Gee J (2000) Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer 82:501–513. doi:10.1054/bjoc.1999.0954
Nicholson R, Hutcheson I, Hiscox S et al (2005) Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr Relat Cancer 12:S29–S36. doi:10.1677/erc.1.00991
Long B, McKibben B, Lynch M, van den Berg H (1992) Changes in epidermal growth factor receptor expression and response to ligand associated with acquired tamoxifen resistance or oestrogen independence in the ZR-75–1 human breast cancer cell line. Br J Cancer 65:865–869
Coutts A, Murphy L (1998) Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells. Cancer Res 58:4071–4074
El-Ashry D, Miller D, Kharbanda S et al (1997) Constituitive Raf-1 kinase activity in breast cancer cells induces both estrogen-independent growth and apoptosis. Oncogene 15:423–435. doi:10.1038/sj.onc.1201198
Gee J, Robertson J, Ellis I et al (2001) Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 95:247–254. doi:10.1002/1097-0215(20010720)95:4≤247::AID-IJC1042≥3.0.CO;2-S
McClelland R, Barrow D, Madden T et al (2001) Enhanced epidermal growth factor receptor signalling in MCF7 breast cancer cells following long-term culture in the presence of the pure antioestrogen ICI 182, 780 (Faslodex). Endocrinology 142:2776–2788. doi:10.1210/en.142.7.2776
Knowlden J, Hutcheson I, Jones H et al (2003) Elevated levels of epidermal growth receptor/c-erB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144:1032–1044. doi:10.1210/en.2002-220620
Williams T, Lisanti M (2004) The caveolin genes: from cell biology to medicine. Ann Med 36:584–595. doi:10.1080/07853890410018899
Couet J, Li S, Okamoto T et al (1997) Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J Biol Chem 272:6525–6533. doi:10.1074/jbc.272.48.30429
Li S, Couet J, Lisanti M (1996) Src tyrosine kinases, Galpha subunits, and H-Ras share a common membrane-anchored scaffolding domain, caveolin. Caveolin binding negatively regulates the auto-activation of Src tyrosine kinases. J Biol Chem 271:29182–29190. doi:10.1074/jbc.271.46.29182
Li S, Okamoto T, Chun M et al (1995) Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem 270:15693–15701. doi:10.1074/jbc.270.26.15693
Couet J, Sargiacomo M, Lisanti MP (1997) Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 272:30429–30438. doi:10.1074/jbc.272.48.30429
Engelman J, Chu C, Lin A et al (1998) Caveolin-mediated regulation of signalling along the p42/p44 MAP kinase cascade in vivo. FEBS Lett 428:205–211. doi:10.1016/S0014-5793(98)00470-0
Engelman J, Lee R, Karnezis A et al (1998) Reciprocal regulation of neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem 273:20448–20455. doi:10.1074/jbc.273.32.20448
Engelman J, Zhang X, Razani B et al (1999) p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and protein kinase a signaling cascades transcriptionally down-regulates caveolin-1 promoter activity. J Biol Chem 274:32333–32341. doi:10.1074/jbc.274.45.32333
Lin M, DiVito M, Merajver S et al (2005) Regulation of pancreatic cancer cell migration and invasion by RhoC GTP ase and caveolin-1. Mol Cancer 4:21. doi:10.1186/1476-4598-4-21
Lee S, Reimer C, Oh P et al (1998) Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 16:1391–1397. doi:10.1038/sj.onc.1201661
Suzuki T, Suzuki Y, Hanada K et al (1998) Reduction of caveolin-1 in tumorigenic human cell hybrids. J Biochem 124:383–388
Zou W, McDaneld L, Smith L (2003) Caveolin-1 haploinsufficiency leads to partial transformation of human breast epithelial cells. Anticancer Res 23:4581–4586
Fiucci G, Ravid D, Reich R et al (2002) Caveolin-1 inhibits anchorage-independent growth, ankoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene 21:2365–2375. doi:10.1038/sj.onc.1205300
Engelman J, Zang X, Lisanti M (1998) Genes encodoing human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett 436:403–410. doi:10.1016/S0014-5793(98)01134-X
Schlegel A, Wang C, Katzenellenbogen B et al (1999) Caveolin-1 potentiates estrogen receptor alpha (ERalpha) signaling. Caveolin-1 drives ligand-independent nuclear translocation and activation of ERalpha. J Biol Chem 274:33551–33556. doi:10.1074/jbc.274.47.33551
Schlegel A, Wang C, Pestell R et al (2002) Ligand-independent activation of oestrogen receptor alpha by caveolin-1. Biochem J 359:203–210. doi:10.1042/0264-6021:3590203
Nasu Y, Timme T, Yang G et al (1998) Suppression of caveolin expression induces androgen sensitivity in metastatic androgen insensitive mouse prostate cancer cell lines. Nat Med 4:1062–1064. doi:10.1038/2048
Yang G, Truong L, Wheeler T et al (1999) Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res 59:5719–5723
Rau K, Kang H, Cha T et al (2005) The mechanisms and managements of hormone therapy resistance in breast and prostate cancers. Endocr Relat Cancer 12:511–532. doi:10.1677/erc.1.01026
Hutcheson I, Knowlden J, Madden T et al (2003) Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 81:81–93. doi:10.1023/A:1025484908380
Cho K, Ryu S, Oh Y et al (2004) Morphological adjustment of senescent cells by modulating caveolin-1 status. J Biol Chem 279:42270–42278. doi:10.1074/jbc.M402352200
Shin J, Kim J, Ryu B et al (2006) Caveolin-1 is associated with VCAM-1 dependent adhesion of gastric cancer cells to endothelial cells. Cell Physiol Biochem 17:211–220. doi:10.1159/000094126
Song K, Li S, Okamoto T et al (1996) Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J Biol Chem 271:9690–9697. doi:10.1074/jbc.271.16.9690
Williams T, Lisanti M (2005) Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Cell Physiol 288:C494–C506. doi:10.1152/ajpcell.00458.2004
Goetz J, Lajoie P, Wiseman S et al (2008) Caveolin-1 in tumour progression: the good, the bad and the ugly. Cancer Metastasis Rev 27:715–735. doi:10.1007/s10555-008-9160-9
Burgermeister E, Liscovitch M, Rocken C et al (2008) Caveats of caveolin-1 in cancer progression. Cancer Lett 268:187–201. doi:10.1016/j.canlet.2008.03.055
Zhang W, Razani B, Altschuler Y et al (2000) Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). J Biol Chem 275:20717–20725. doi:10.1074/jbc.M909895199
Park D, Hyangkyu L, Frank P et al (2002) Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation, and hyperactivation of the Jak-2/STAT5a signalling cascade. Mol Biol Cell 13:3416–3430. doi:10.1091/mbc.02-05-0071
Williams T, Medina F, Badano I et al (2004) Caveolin-1 gene promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. J Biol Chem 279:51630–51646. doi:10.1074/jbc.M409214200
Williams T, Sotgia F, Lee H et al (2006) Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis. Am J Pathol 169:1784–1801. doi:10.2353/ajpath.2006.060590
Hayashi K, Matsuda S, Machida K et al (2001) Invasion activating caveolin-1 mutation in human scirrhous breast cancers. Cancer Res 61:2361–2364
Pinilla S, Honrado E, Hardisson E et al (2006) Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 99:85–90. doi:10.1007/s10549-006-9184-1
Perrone G, Altomare V, Zagami M et al (2009) Caveolin-1 expression in human breast lobular cancer progression. Mod Pathol 22:71–78. doi:10.1038/modpathol.2008.154
Zschocke J, Manthey D, Bayatti N et al (2002) Estrogen receptor alpha-mediated silencing of caveolin gene expression in neuronal cells. J Biol Chem 277:38772–38780. doi:10.1074/jbc.M205664200
Razandi M, Oh P, Pedram A et al (2002) ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol Endocrinol 16:100–115. doi:10.1210/me.16.1.100
Li T, Sotgia F, Vuolo M et al (2006) Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am J Pathol 168:1998–2013. doi:10.2353/ajpath.2006.051089
Park S, Kim J, Kim Y (2005) Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathol 47:625–630. doi:10.1111/j.1365-2559.2005.02303.x
Sagara Y, Mimori K, Yoshinaga K et al (2004) Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer. Br J Cancer 91:959–965
Britton D, Hutcheson I, Knowlden J et al (2006) Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 96:131–146. doi:10.1007/s10549-005-9070-2
Jones K, Jiang X, Yamamoto Y et al (2004) Tuberin is a component of lipid rafts and mediates caveolin-1 localisation: role of TSC2 in post-Golgi transport. Exp Cell Res 295:512–524. doi:10.1016/j.yexcr.2004.01.022
Jiang X, Yeung S (2006) Regulation of microtubule-dependent protein transport by the TSC2/mammalian target of rapamycin pathway. Cancer Res 66:2006
Aoki T, Nomura R, Fujimoto T (1999) Tyrosine phosphorylation of caveolin-1 in the endothelium. Exp Cell Res 253:629–636. doi:10.1006/excr.1999.4652
Nomura R, Fujimoto T (1999) Tyrosine-phosphorylated caveolin-1: immunolocalization and molecular characterization. Mol Biol Cell 10:975–986
Li S, Seitz R, Lisanti M (1996) Phosphorylation of caveolin by src tyrosine kinases. The alpha-isoform of caveolin is selectively phosphorylated by v-Src in vivo. J Biol Chem 271:3863–3868. doi:10.1074/jbc.271.7.3863
Hiscox S, Morgan L, Green T et al (2006) Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 97:263–274. doi:10.1007/s10549-005-9120-9
Lee H, Volonte D, Galbiati F et al (2000) Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol Endocrinol 14:1750–17575. doi:10.1210/me.14.11.1750
Khan EM, Heidinger JM, Levy M et al (2006) Epidermal growth factor receptor exposed to oxidative stress undergoes Src- and caveolin-1-dependent perinuclear trafficking. J Biol Chem 281:14486–14493. doi:10.1074/jbc.M509332200
Dittman K, Mayer C, Kehlbach R, Rodemann H (2008) The radioprotector Bowman-Birk proteinase inhibitor stimulates DNA repair via the epidermal growth factor receptor phosphorylation and nuclear transport. Radiother Oncol 86:375–382. doi:10.1016/j.radonc.2008.01.007
Joshi B, Strugnell S, Goetz JG et al (2008) Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. Cancer Res 68:8210–8220. doi:10.1158/0008-5472.CAN-08-0343
Van den Eynden G, Van Laere S, Van der Auwera I et al (2006) Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat 95:219–228. doi:10.1007/s10549-005-9002-1
Johnston SR (2005) Clinical trials of intracellular signal transductions inhibitors for breast cancer—a strategy to overcome endocrine resistance. Endocr Relat Cancer 1(suppl):S145–S157. doi:10.1677/erc.1.00992
Acknowledgments
The authors would like to thank Carol Dutkowski and Denise Barrow for their excellent technical assistance. To Dr. Andrew Hollins for construction of the recombinant caveolin-1 construct and Dr. Arwyn T. Jones for advice on subcellular fractionation. This research was generously supported by the Tenovus organisation and a Welsh School of Pharmacy studentship to NBPT. ‘Iressa’ and ‘Faslodex’ are trademarks of the AstraZeneca group of companies.
Author information
Authors and Affiliations
Corresponding author
Additional information
Nicholas B.·P. Thomas, Iain R. Hutcheson and Lee Campbell have contributed equally to this work.
Rights and permissions
About this article
Cite this article
Thomas, N.B.P., Hutcheson, I.R., Campbell, L. et al. Growth of hormone-dependent MCF-7 breast cancer cells is promoted by constitutive caveolin-1 whose expression is lost in an EGF-R-mediated manner during development of tamoxifen resistance. Breast Cancer Res Treat 119, 575–591 (2010). https://doi.org/10.1007/s10549-009-0355-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-009-0355-8